好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

TDP-43 Cooperates With Nuclear Exosome Targeting Complex in Regulating SCARNA2 Metabolism
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (11:45 AM-12:45 PM)
9-020

To elucidate the intracellular molecular mechanism of TAR DNA-binding protein of 43 kDa(TDP-43)and its role in the pathogenesis of amyotrophic lateral sclerosis (ALS).

TDP-43 has been implicated in diverse aspects of RNA metabolism, including transcriptional regulation, mRNA transport and degradation. Recently, it has been shown that TDP-43 is involved in regulation of non-coding RNA (ncRNA) metabolism. Nevertheless, the molecular details of how TDP-43 contributes to RNA surveillance remain unclear. We performed several omics analysis to address the molecular mechanism of TDP-43 in regulation of ncRNA metabolism.

To identify RNAs bound to TDP-43, we performed ultraviolet RNA immunoprecipitation (UV-RIP) followed by RNA-seq using doxycycline-inducible FLAG-TDP-43 TREx293 cells. To identify TDP-43-associated proteins, we conducted immunoprecipitation–mass spectrometry analysis under the same conditions. To investigate functional consequences, we established TDP-43-FKBP12F36V knock-in cells using the dTAG system to induce rapid protein degradation, followed by RNA-seq analysis. In addition, single and double knockdowns of TDP-43 and NEXT components were performed, and RNA levels were measured by RT-qPCR. We used ChatGPT (GPT-5; OpenAI) to assist with R code for figure preparation. Analyses and data interpretation were conducted by the authors.

UV-RIP-Seq revealed SCARNA2 as RNA bound by TDP-43. Proteomic analysis identified NEXT complex as TDP-43 interacting factor. dTAG-mediated TDP-43 degradation or knockdown of the component of NEXT complex, RBM7 increased SCARNA2 levels, while further increase of SCARNA2 was not observed under simultaneous depletion of TDP-43 and RBM7. These results indicate that TDP-43 and NEXT complex cooperatively function in the same pathway to regulate the degradation of SCARNA2.
Our findings demonstrate that TDP-43 cooperates with the NEXT complex to mediate the degradation of SCARNA2. This work uncovers a novel molecular mechanism of RNA surveillance and provides new insight into how dysregulation of TDP-43 may contribute to the pathogenesis of ALS.
Authors/Disclosures
Yuki Oshima, MD
PRESENTER
Dr. Oshima has nothing to disclose.
Yoko Suzuki, MD, PhD Dr. Suzuki has nothing to disclose.
Ryota Abe, MD Mr. Abe has nothing to disclose.
Ogawa Shintaro, MD Dr. Shintaro has nothing to disclose.
Yoko Ike, MS Mrs. Ike has nothing to disclose.
Hiroaki Yaguchi, MD Dr. Yaguchi has nothing to disclose.
Yukitoshi Takahashi, MD, PhD Dr. Takahashi has received personal compensation in the range of $0-$499 for serving as an Expert Witness for Ono Pharamaceutical.
Ichiro Yabe, MD, PhD (Hokkaido University) Dr. Yabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Yabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for DaiichiSankyo. Dr. Yabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SumitomoPharma. Dr. Yabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for KyowaKirin. Dr. Yabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam Japan. Dr. Yabe has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly Japan. The institution of Dr. Yabe has received research support from Toppan. The institution of Dr. Yabe has received research support from Ceres. The institution of Dr. Yabe has received research support from Hakuyo-Kai. The institution of Dr. Yabe has received research support from Choan-Kai.